SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates11/8/2004 2:48:30 PM
  Read Replies (2) of 3661
 
Actelion down 20-odd% in Europe today on this -

Switzerland-based biopharmaceutical firm Actelion Ltd (Zurich: ATLN.S - news) has stopped a study evaluating the efficacy and safety of tezosentan in acute heart failure due to poor hemodynamic efficacy results.

Switzerland-based biopharmaceutical firm Actelion Ltd has stopped a study evaluating the efficacy and safety of tezosentan in acute heart failure due to poor hemodynamic efficacy results.

This decision, to discontinue the study, is consistent with recommendations made by the steering committee and the independent Data Safety Monitoring Board (DSMB).

The VERITAS study evaluated mortality/morbidity and dyspnea benefits as co-primary clinical endpoints in acute heart failure (AHF) patients receiving standard therapy of care and either tezosentan or placebo.

The DSMB reported that there were no safety issues in the study but, although hemodynamic effects were observed in the treatment arm and were consistent with previous studies, there was too remote a chance for the efficacy endpoints to become statistically significant within this study.

Actelion will now reallocate resources to strengthen brands and R&D, reinforcing its focus on Tracleer and Zavesca and working to further accelerate development of its broad clinical and pre-clinical pipeline...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext